Tigecycline's Core Patents and Initial Exclusivity
Tigecycline, sold as Tygacil by Wyeth (now Pfizer), received FDA approval in 2005 for complicated skin and intra-abdominal infections. Its main composition patent, US Patent 5,939,277, covered the compound and expired in 2015, with pediatric exclusivity extending it to June 2016. This granted 11 years of market exclusivity from launch, blocking generics until then.[1][2]
How Pfizer Extended Protection Through Secondary Patents
Pfeth delayed generics beyond 2015 via secondary patents on formulations, methods of use, and manufacturing processes:
- Formulation patents: US Patent 7,709,618 (crystalline form) and US 7,910,583 (IV formulation) extended to 2026-2027. These claimed tigecycline's specific particle size and stability improvements, required for injectables.
- Method-of-use patents: US 7,833,988 (for diabetic foot infections) listed until 2022, broadening indications to deter Paragraph IV challenges.
- Patent Term Extensions (PTE): FDA granted 1,357 days PTE on key patents under 35 USC 156 for regulatory review delays, pushing expiration to 2022-2027.[2]
Pfizer listed these in the FDA's Orange Book, triggering 30-month stays on ANDA approvals for challengers filing Paragraph IV certifications.
Key Litigation Delaying Generic Entry
Generic firms like Mylan and Sandoz challenged validity in 2014-2016 ANDA litigations:
- Mylan case (2016): Court upheld formulation patents '618 and '583 as valid/non-obvious; Federal Circuit affirmed in 2018, blocking Mylan until 2024 (with PTE).[3]
- Apotex settlement (2017): Apotex licensed entry in 2022, but litigation delays pushed it further.
- COVID-19 impact: FDA prioritized reviews slowed ANDA approvals; no generics launched until 2023.
These suits created uncertainty, deterring investment and entry.
When Did Patents Finally Expire and Generics Enter?
- Primary compound patent: June 24, 2016.
- Key blockers expired 2022-2024; first FDA tentative generic approval (Mylan) in 2020, final in 2023.
- Market entry: Natco and others launched AB-rated generics in October 2023 after final court rulings and FDA sign-off.[1][4]
No generics sold in US before 2023 despite 2016 compound expiry.
Authorized Generics and Pricing Impact
Pfizer launched authorized generic in 2023, capturing 80% share initially and keeping prices high (~$1,000/dose vs. $100 generic).[4]
Comparison to Similar Antibiotics
Unlike meropenem (generics 2008 post-2004 expiry), tigecycline's dense secondary patent thicket (15+ Orange Book listings) added 8 years delay, mirroring evergreening in antibiotics like daptomycin.[2]
Sources:
[1] FDA Orange Book for Tygacil
[2] DrugPatentWatch.com - Tygacil Patents
[3] Federal Circuit ruling, Mylan v. Pfizer (2018)
[4] FDA Generic Approvals Tracker